335 related articles for article (PubMed ID: 37004015)
1. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
Song C; Shang F; Tu W; Liu X
BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
3. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
5. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment.
Zhu Z; Ye W; Wu X; Lin S; Xu J; Li L; Li J; Wang H; Huang Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33350431
[TBL] [Abstract][Full Text] [Related]
7. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
[TBL] [Abstract][Full Text] [Related]
8. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer.
Shen Y; Xue J; Yu J; Jiang Y; Bu J; Zhu T; Gu X; Zhu X
World J Surg Oncol; 2022 Dec; 20(1):398. PubMed ID: 36517818
[TBL] [Abstract][Full Text] [Related]
10. Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
Chen H; Liu Y; Yin Z; Chen H; Wang Y; Qian Y
Cell Cycle; 2023 May; 22(9):1077-1100. PubMed ID: 36757135
[TBL] [Abstract][Full Text] [Related]
11. CD1C is associated with breast cancer prognosis and immune infiltrates.
Chen X; Zhang J; Lei X; Yang L; Li W; Zheng L; Zhang S; Ding Y; Shi J; Zhang L; Li J; Tang T; Jia W
BMC Cancer; 2023 Feb; 23(1):129. PubMed ID: 36755259
[TBL] [Abstract][Full Text] [Related]
12. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
Lin J; Chen Y; Zhang Z; Qi F; Zhang M
Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.
Wu Q; Zheng S; Lin N; Xie X
BMC Med Genomics; 2023 Apr; 16(1):87. PubMed ID: 37098532
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
16. Effect of activating cancer-associated fibroblasts biomarker TNC on immune cell infiltration and prognosis in breast cancer.
Huang T; Lu C; Zhang Y; Lin BY; Zhang ZJ; Zhu D; Wang L; Lu Y
Ann Med; 2023; 55(2):2250987. PubMed ID: 38375814
[TBL] [Abstract][Full Text] [Related]
17. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
[TBL] [Abstract][Full Text] [Related]
18. Performance of a PLK1-based immune risk model for prognosis and treatment response prediction in breast cancer.
Chen Y; You Y; Wu Q; Wu J; Lin S; Sun Y; Cui Z
Cancer Med; 2023 May; 12(9):11020-11039. PubMed ID: 36951624
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of DAAM2 in lower grade glioma, liver cancer, and breast cancer.
Li Z; Wei X; Zhu Y
Clin Transl Oncol; 2023 Jul; 25(7):2224-2238. PubMed ID: 36790676
[TBL] [Abstract][Full Text] [Related]
20. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]